SSTR2 and hepatocellular carcinoma: The increased tumor binding with antagonists opens up the potential indications for SSTR2 targeting to tumors which have a relatively lower expression of SSTR2 compared to NET such as small cell lung cancer, hepatocellular carcinoma and breast cancer.